[go: up one dir, main page]

CL2008000411A1 - Composicion farmaceutica que comprende un primer compuesto que incrementa el ph del estomago, un segundo agente que reduce el ph y al menos un tercer agente seleccionado entre una vitamina, un mineral y otro farmaco; y su uso para mejorar la absorcio - Google Patents

Composicion farmaceutica que comprende un primer compuesto que incrementa el ph del estomago, un segundo agente que reduce el ph y al menos un tercer agente seleccionado entre una vitamina, un mineral y otro farmaco; y su uso para mejorar la absorcio

Info

Publication number
CL2008000411A1
CL2008000411A1 CL200800411A CL2008000411A CL2008000411A1 CL 2008000411 A1 CL2008000411 A1 CL 2008000411A1 CL 200800411 A CL200800411 A CL 200800411A CL 2008000411 A CL2008000411 A CL 2008000411A CL 2008000411 A1 CL2008000411 A1 CL 2008000411A1
Authority
CL
Chile
Prior art keywords
agent
pharmaco
stomach
vitamin
mineral
Prior art date
Application number
CL200800411A
Other languages
English (en)
Inventor
Hermelin Jonathan David B Marc
Original Assignee
Drugtech Corp Soc Organizada B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugtech Corp Soc Organizada B filed Critical Drugtech Corp Soc Organizada B
Publication of CL2008000411A1 publication Critical patent/CL2008000411A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL200800411A 2007-02-09 2008-02-08 Composicion farmaceutica que comprende un primer compuesto que incrementa el ph del estomago, un segundo agente que reduce el ph y al menos un tercer agente seleccionado entre una vitamina, un mineral y otro farmaco; y su uso para mejorar la absorcio CL2008000411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88904707P 2007-02-09 2007-02-09

Publications (1)

Publication Number Publication Date
CL2008000411A1 true CL2008000411A1 (es) 2008-08-08

Family

ID=39686026

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800411A CL2008000411A1 (es) 2007-02-09 2008-02-08 Composicion farmaceutica que comprende un primer compuesto que incrementa el ph del estomago, un segundo agente que reduce el ph y al menos un tercer agente seleccionado entre una vitamina, un mineral y otro farmaco; y su uso para mejorar la absorcio

Country Status (7)

Country Link
US (1) US20080193531A1 (es)
AR (1) AR065246A1 (es)
CL (1) CL2008000411A1 (es)
PE (1) PE20090038A1 (es)
TW (1) TW200843802A (es)
UY (1) UY30905A1 (es)
WO (1) WO2008100767A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2368553B1 (en) 2003-04-08 2014-12-31 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
IL169678A (en) 2005-07-14 2010-11-30 Innova Sa Sweetener compositions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
ITMI20071979A1 (it) * 2007-10-12 2009-04-13 Massimo Baldacci Formulazioni farmaceutiche contenenti ferro bisglicinato chelato
GB0808835D0 (en) * 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
US20100307542A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Method of Reducing Surface Oil on Encapsulated Material
US9968564B2 (en) * 2009-06-05 2018-05-15 Intercontinental Great Brands Llc Delivery of functional compounds
US8859003B2 (en) * 2009-06-05 2014-10-14 Intercontinental Great Brands Llc Preparation of an enteric release system
US20100310726A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
MX2012000892A (es) 2009-07-21 2012-06-01 Keryx Biopharmaceuticals Inc Formas de dosificacion de citrato ferrico.
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
EA029096B1 (ru) 2010-03-11 2018-02-28 Вайет Ллк Твердая лекарственная форма для перорального введения, содержащая метилналтрексон
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US9433583B2 (en) 2011-04-22 2016-09-06 Frank J. Farrell Colon vitamin
PL2659881T3 (pl) * 2012-04-30 2018-05-30 Tillotts Pharma Ag Formulacja leku o opóźnionym uwalnianiu
RU2493845C1 (ru) * 2012-06-07 2013-09-27 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
FR2992219B1 (fr) * 2012-06-22 2014-07-11 Aditec Lab Composition pour le traitement de l'hypocalcemie chez les ruminants
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
MX370447B (es) * 2013-03-14 2019-12-13 Amip Llc Composición nutricional reservada en fósforo.
AU2014275307B2 (en) * 2013-06-06 2017-06-15 Amip, Llc Iron supplement
JP6273356B2 (ja) 2013-10-29 2018-01-31 ティロッツ・ファルマ・アクチエンゲゼルシャフトＴｉｌｌｏｔｔｓ Ｐｈａｒｍａ Ａｇ 遅延放出性薬物製剤
US10034899B2 (en) 2013-11-27 2018-07-31 BioPharmX, Inc. Solid oral dosage form for breast symptoms
US10231476B2 (en) 2014-04-04 2019-03-19 Douxmatok Ltd Sweetener compositions and foods, beverages, and consumable products made thereof
US10207004B2 (en) * 2014-04-04 2019-02-19 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
US20160242439A1 (en) 2014-04-04 2016-08-25 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
WO2015175479A1 (en) * 2014-05-13 2015-11-19 Steven Baranowitz Pharmaceutical composition
US20160339086A1 (en) * 2015-05-19 2016-11-24 Suzy Cohen Compositions and methods for treating thyroid disease
RU2715906C2 (ru) * 2015-05-29 2020-03-04 Джонсон энд Джонсон Консьюмер Инк. Применение органического экстракта цитрусовых с высокой противомикробной активностью и ксилита в качестве системы консервантов в жидкостях, эмульсиях, суспензиях, кремах и антацидах
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
EP3368498A4 (en) 2015-10-27 2019-06-12 Cytozyme Animal Nutrition, Inc. ANIMAL NUTRITIONAL COMPOSITIONS AND RELATED METHODS
US10702590B2 (en) 2016-04-12 2020-07-07 Script Essentials, Llc Compositions and methods for treating thyroid disease
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CA3033065A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
US9974804B1 (en) * 2017-09-08 2018-05-22 David Lloyd Smith Strontium-based composition, product, and method of using the same to control progression of osteoarthritis osteoporosis and tooth decay
EP3720844A4 (en) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation MEDICINAL COMPOSITIONS
CN108498868B (zh) * 2018-04-03 2020-09-15 北京大学口腔医学院 具有细胞外基质电学拓扑特征的带电复合膜及其制备方法
MX2022003756A (es) 2019-09-30 2022-05-03 Procter & Gamble Composiciones para el cuidado bucal que comprenden acido beta de lupulo e ion metalico.
BR112023019578A2 (pt) * 2021-03-25 2023-11-14 Procter & Gamble Composições bucais comestíveis que compreendem lúpulo
CN113491302A (zh) * 2021-07-09 2021-10-12 北京东方天合生物技术有限责任公司 一种预防奶牛酮病的过瘤胃烟酸添加剂及其制备方法
US20240050388A1 (en) * 2022-08-15 2024-02-15 Biolink Life Sciences, Inc. Calcium succinate monohydrate formulation
CN115463124B (zh) * 2022-11-02 2024-04-05 海而思（郑州）科技有限公司 一种补铁泡腾片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076747A (en) * 1960-02-03 1963-02-05 Haessle Ab Pharmaceutical iron preparations
JPS57156419A (en) * 1981-03-24 1982-09-27 Kyowa Chem Ind Co Ltd Remedy for sideropenia
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US6251883B1 (en) * 1991-01-08 2001-06-26 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
CN100341483C (zh) * 2000-02-28 2007-10-10 维克丘拉有限公司 口服药物输递中或涉及口服药物输递的改进
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
US20050282756A1 (en) * 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system

Also Published As

Publication number Publication date
UY30905A1 (es) 2008-09-02
AR065246A1 (es) 2009-05-27
WO2008100767A1 (en) 2008-08-21
TW200843802A (en) 2008-11-16
PE20090038A1 (es) 2009-01-30
US20080193531A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
CL2008000411A1 (es) Composicion farmaceutica que comprende un primer compuesto que incrementa el ph del estomago, un segundo agente que reduce el ph y al menos un tercer agente seleccionado entre una vitamina, un mineral y otro farmaco; y su uso para mejorar la absorcio
CL2008000510A1 (es) Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
BRPI0811317A2 (pt) Combinação, embalagem farmcêutica, kit ou mbalagem par apaciente, agente auxiliar, compsoto, usos de um agente auxiliar e de um composto, e, processo para a produção de uma combinação
CL2013003455A1 (es) Uso de compuestos inhibidores de sglt-2 derivados de benceno, sustituidos por glucopiranosilo para prevenir, desacelerar la progresion, retrasar o tratar un trastorno metabolico en un pacientes con un agente neuroleptico; uso de la combinacion del inhibidor de sglt2 con un neuroleptico; y composicion farmaceutica de la combinacion.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2008000133A1 (es) Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
CL2007001870A1 (es) Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
BRPI0921249A2 (pt) uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterapico na preparação de uma composição,e composições para o tratamento do cãncer.
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
CL2012000392A1 (es) Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos para tratar cancer en combinacion con fludarabina .
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
BRPI0809522A2 (pt) Composição farmacêutica sólida, métodos para estabilizar um composto, e para melhorar dissolução de um composto, e, uso de um agente de controle de ph.